Related references
Note: Only part of the references are listed.TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
Thorsten Zenz et al.
BLOOD (2009)
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
Davide Rossi et al.
CLINICAL CANCER RESEARCH (2009)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
F. Dicker et al.
LEUKEMIA (2009)
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia:: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL
O. G. Best et al.
LEUKEMIA (2008)
Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia
Wei Xu et al.
LEUKEMIA RESEARCH (2008)
Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia
Michael R. Grever et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia
A Kröber et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia
C Mayr et al.
BLOOD (2006)
Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection
T Soussi et al.
CLINICAL CANCER RESEARCH (2006)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia
PD Thornton et al.
HEMATOLOGY JOURNAL (2004)
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy
I Sturm et al.
CELL DEATH AND DIFFERENTIATION (2003)
Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia
K Lin et al.
BLOOD (2002)
p53 dysfunction in B-cell chronic lymphocytic leukemia:: inactivation of ATM as an alternative to TP53 mutation
AR Pettitt et al.
BLOOD (2001)
Share Paper
